The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Uy Ear - Mizuho Securities USA - Analyst
: First, congratulations on the two deals. Yeah, may, a question that we've been getting is maybe just help us understand the process that was
involved in the deal, why, the, were there other competitive bidders for particularly for NDV01.
And why these companies chose to go with you if there are other bidders over the other bidders, first question, and I guess the second question
we have is, at the upcoming AUA meeting, what should we kind of expect in terms of, potential data, and I think the abstract will be out on April
11 or something. Will there be data in the abstract or the sort of the key data will will be at the conference?
Question: Uy Ear - Mizuho Securities USA - Analyst
: So is our is the expected data is that primarily from the 3 months of induction and any particular. Yeah maybe.
Question: Basma Radwan - Leerink Partners - Analyst
: This is Basma on for Marc.
Our first question, could you please elaborate a little bit on the safety profile of soprano loan? And also the, we have a question on the second
indication, which is better reallyli. Now, given that the space is a little bit crowded after the recent approval, of the first agent in this, indication, do
you think, That's, it's going to be a valuable second opportunity for the drug.
Question: Andrew Tsai - Jefferies - Analyst
: Congrats on in licensing these compounds pretty cool, maybe for soprano loan, what is the approvable endpoint for, pivotal studies and what did
you see in the Phase 2A on that endpoint and how would that compare to the dopamine blockers and antipsychotics, used for Tourette's?
Question: Andrew Tsai - Jefferies - Analyst
: And then for the bladder cancer compound, after you you report the data at the medical conference, does it make sense in your upcoming FDA
meeting to discuss whether an accelerated approval pathway is possible?
Question: Andrew Tsai - Jefferies - Analyst
: And then my last question is can we expect you to license more compounds this year?
|
